基因疗法在治疗与年龄相关的黄斑退化方面的进展
Efstratia Amaxilati1, Eleftherios Chatzimichail2, Georgios N Tsiropoulos1
1Department of Ophthalmology, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Cells
|February 26, 2026
概括
基因疗法提供了一种有前途的方法来管理与年龄相关的黄斑变性 (AMD),通过在一次注射后提供持续治疗. 这篇评论探讨了基因疗法.
科学领域:
- 眼科和基因疗法治疗
- 生物技术和药物供应 生物技术和药物供应
背景情况:
- 与年龄相关的黄斑变性 (AMD) 导致不可逆转的视力丧失,目前对新血管AMD (nAΜD) 和地理缩 (GA) 的治疗有局限性.
- 对于nAMD而言,频繁的静脉内抗VEGF注射会造成严重的治疗负担.
- 现有的GA治疗方法只能适度地减缓疾病的进展.
研究的目的:
- 审查在AMD眼部基因治疗的生物基础,载体系统和输送方法.
- 总结在nAMD中持续抗VEGF表达的临床策略,并对GA进行补充调制.
- 突出AMD基因疗法试验的进展,重点是减少注射负担和改善终点.
主要方法:
- 审查腺相关病毒 (AAV) 载体平台,包括囊体工程.
- 对分区特定的输送路径的分析:视膜内,腹膜下和腹膜上.
- 在nAMD和GA中对基因疗法方法的临床试验数据的综合.
主要成果:
- 基因疗法旨在维持眼内治疗性蛋白质表达,减少治疗负担.
- 临床试验越来越多地关注解剖结果和生物标志物.
- 关键的挑战包括管理眼内炎症,免疫反应,转基因表达变异性,手术风险和制造/成本限制.
结论:
- 眼部基因疗法为持久的,有针对性的AMD管理提供了一个可行的策略.
- 进一步强大的临床试验和长期随访对于确定基因治疗在AMD治疗中的作用至关重要.
- 对临床翻译来说,解决分娩,表达和安全方面的挑战至关重要.
关键词:
这就是VEGF.腺相关病毒的病毒.与年龄相关的黄斑变性.补充补充补充补充补充补充补充.基因治疗的基因疗法地理缩是地理上的缩.内内真体 内内真体新血管性AMD.这是一种子关节.这是一种超体性体.更多相关视频
相关概念视频
01:22iPS Cell Differentiation
3.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K
00:59Gene Therapy
27.8K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.8K
01:27Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
01:28Angle Closure Glaucoma: Treatment
1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K